Keng-Hsueh Lan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3149803/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Synergistic effect of Abraxane that combines human IL15 fused with an albuminâ€binding domain on murine models of pancreatic ductal adenocarcinoma. Journal of Cellular and Molecular Medicine, 2022, 26, 1955-1968.	3.6	4
2	Real-World Evaluation of Modern Adjuvant Radiotherapy in Women with Stage IB Endometrial Cancer. Cancers, 2021, 13, 1386.	3.7	1
3	Affibody-conjugated 5-fluorouracil prodrug system preferentially targets and inhibits HER2-expressing cancer cells. Biochemical and Biophysical Research Communications, 2021, 582, 137-143.	2.1	1
4	Impact of adjuvant radiotherapy on the survival of women with optimally resected stage III endometrial cancer in the era of modern radiotherapy: a retrospective study. Radiation Oncology, 2020, 15, 72.	2.7	14
5	Extended-field bone marrow sparing radiotherapy for primary chemoradiotherapy in cervical cancer patients with para-aortic lymphadenopathy: Volumetric-modulated arc therapy versus helical tomotherapy. Journal of X-Ray Science and Technology, 2020, 28, 111-124.	1.0	6
6	Maintenance BEZ235 Treatment Prolongs the Therapeutic Effect of the Combination of BEZ235 and Radiotherapy for Colorectal Cancer. Cancers, 2019, 11, 1204.	3.7	11
7	Prognostic significance of tumor-infiltrating lymphocytes in patients with operable tongue cancer. Radiation Oncology, 2018, 13, 157.	2.7	24
8	Tumor compactness improves the preoperative volumetry-based prediction of the pathological complete response of rectal cancer after preoperative concurrent chemoradiotherapy. Oncotarget, 2017, 8, 7921-7934.	1.8	15
9	<i>Helicobacter pylori</i> CagA protein activates Akt and attenuates chemotherapeutics-induced apoptosis in gastric cancer cells. Oncotarget, 2017, 8, 113460-113471.	1.8	8
10	Impact of androgen-deprivation therapy on the outcome of dose-escalation prostate cancer radiotherapy without elective pelvic irradiation. Asian Journal of Andrology, 2017, 19, 596.	1.6	3
11	Good tolerance and longâ€term complete remission after definitive intensityâ€modulated radiotherapy for locally advanced head and neck cancer in a patient with human immunodeficiency virus infection: A case report and literature review. Head and Neck, 2015, 37, E186-90.	2.0	3
12	Prolonged Treatment Time Deteriorates Positioning Accuracy for Stereotactic Radiosurgery. PLoS ONE, 2015, 10, e0123359.	2.5	16
13	The Response, Outcome and Toxicity of Aggressive Palliative Thoracic Radiotherapy for Metastatic Non-Small Cell Lung Cancer Patients with Controlled Extrathoracic Diseases. PLoS ONE, 2015, 10, e0145936.	2.5	15
14	Preoperative Prognostic Neurologic Index for Glioblastoma Patients Receiving Tumor Resection. Annals of Surgical Oncology, 2014, 21, 3992-3998.	1.5	6
15	A DNA vaccine against cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) prevents tumor growth. Biochemical and Biophysical Research Communications, 2013, 440, 222-228.	2.1	15
16	Amiodarone inhibits the entry and assembly steps of hepatitis C virus life cycle. Clinical Science, 2013, 125, 439-448.	4.3	21
17	Clinicopathologic features and responses to radiotherapy of myeloid sarcoma. Radiation Oncology, 2013, 8, 245.	2.7	26
18	5-Fluorocytosine combined with Fcy–hEGF fusion protein targets EGFR-expressing cancer cells. Biochemical and Biophysical Research Communications, 2012, 428, 292-297.	2.1	4

Keng-Hsueh Lan

#	Article	IF	CITATIONS
19	14-3-3ζ Overexpression Defines High Risk for Breast Cancer Recurrence and Promotes Cancer Cell Survival. Cancer Research, 2009, 69, 3425-3432.	0.9	175
20	Preclinical Testing of Clinically Applicable Strategies for Overcoming Trastuzumab Resistance Caused by PTEN Deficiency. Clinical Cancer Research, 2007, 13, 5883-5888.	7.0	195
21	Selective Inhibition of ErbB2-Overexpressing Breast Cancer In vivo by a Novel TAT-Based ErbB2-Targeting Signal Transducers and Activators of Transcription 3–Blocking Peptide. Cancer Research, 2006, 66, 3764-3772.	0.9	118
22	Mechanisms of Trastuzumab Resistance and Their Clinical Implications. Annals of the New York Academy of Sciences, 2005, 1059, 70-75.	3.8	68
23	ErbB2 Promotes Src Synthesis and Stability: Novel Mechanisms of Src Activation That Confer Breast Cancer Metastasis. Cancer Research, 2005, 65, 1858-1867.	0.9	264
24	Activation of the Akt/Mammalian Target of Rapamycin/4E-BP1 Pathway by ErbB2 Overexpression Predicts Tumor Progression in Breast Cancers. Clinical Cancer Research, 2004, 10, 6779-6788.	7.0	293
25	PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell, 2004, 6, 117-127.	16.8	1,693
26	Phosphorylation on Tyrosine-15 of p34Cdc2 by ErbB2 Inhibits p34Cdc2 Activation and Is Involved in Resistance to Taxol-Induced Apoptosis. Molecular Cell, 2002, 9, 993-1004.	9.7	124
27	Localizing the EGF receptor - Reply. Nature Cell Biology, 2002, 4, E22-E23.	10.3	9
28	Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Research, 2002, 62, 5703-10.	0.9	85